跳至主要内容
临床试验/NL-OMON41716
NL-OMON41716已完成不适用

therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritis - therapeutic drug monitoring of adalimumab in rheumatoid arthritis

Reade, centrum voor Revalidatie en Reumatologie0 个研究点目标入组 55 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • RA according to the ACR 1987 criteria
  • Adalimumab treatment for at least 28 weeks
  • Trough adalimumab level > 12 mg/L
  • Treating rheumatologist is convinced of the benefit of adalimumab continuation
  • Written informed consent

排除标准

  • Scheduled surgery in the next 6 months or other pre planned reasons for treatment discontinuation.

研究者

发起方
Reade, centrum voor Revalidatie en Reumatologie

相似试验

尚未招募
不适用
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.rheumatoid arthritisadalimumabtherapeutic drug monitoring
NL-OMON29559ReumafondsReade, centrum voor revalidatie en reumatologie102
已完成
3 期
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shock
DRKS00011159Friedrich-Schiller-Universität Jena254
已完成
不适用
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Studyadvanced tumors for which no treatment options are availablerenal cell cancer10038588
NL-OMON37356eids Universitair Medisch Centrum13
进行中(未招募)
1 期
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactam
EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208
撤回
不适用
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
ACTRN12620000447954Royal Brisbane & Women's Hospital150